Valion Bio Inc(VBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:38 AM ET (Korea 9/29 17:38)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -233.18 | Insider Own | 0.2% | Shs Outstand | 0.9M | Perf Week | 13.45% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.9M | Perf Month | -11.91% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 11.96% | Short Float | 4.32% | Perf Quarter | -80.36% |
| Income | -0.01B | P/S | 4.99 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.06 | Perf Half Y | -88.38% |
| Sales | 0.00B | P/B | 0.11 | EPS next 5Y | - | ROA | -156% | Short Interest | 0.04M | Perf YTD | -92.55% |
| Book/sh | 25.57 | P/C | 1.14 | EPS past 3/5Y | 83.77% 59.16% | ROE | -178.18% | 52W High | -96.57% ($78.75) | Perf Year | -96.35% |
| Cash/sh | 2.38 | P/FCF | - | Sales past 3/5Y | - | ROIC | -26.1% | 52W Low | 31.71% ($2.05) | Perf 3Y | -99.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.22% | Gross Margin | -58.51% | Volatility(W/M) | 33.54% 19.22% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 52.79 | Sales Y/Y TTM | -49.63% | Oper. Margin | -1548.96% | ATR (14) | 0.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.86 | EPS Q/Q | 16.56% | Profit Margin | -1557.26% | RSI (14) | 42.1 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.11 | Sales Q/Q | -100% | SMA20 | 3.57% ($2.61) | Beta | 1.79 | Target Price | - |
| Payout | - | Debt/Eq | 1.47 | Earnings | 2026/5/14 | SMA50 | -41.29% ($4.6) | Rel Volume | 0.36 | Prev Close | $3.03 |
| Employees | 52 | LT Debt/Eq | 1.42 | EPS/Sales Surpr. | - | SMA200 | -86.49% ($19.99) | Avg Volume(3M) | 0.61M | Price | $2.7 |
| IPO | 2021/11/11 | Option/Short | No/Yes | Trades | 1413 | Volume | 220,632 | Change | -10.89% |
A biotech company developing immunomodulatory therapeutics. The company rebranded in April 2026 (formerly Tivic Health) and is advancing a late-stage clinical candidate through the regulatory approval pathway while pursuing its own path to revenue generation through a contract manufacturing business.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded less than usual That is 36% of its average volume.
VBIO has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $499. Peers typically go for $1,227.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.7%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.0%.
Tap to view numbers
It ranks #581 of 592 in the industry
Based on market cap of $2M.
FAQ
What kind of company is VBIO?
VBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VBIO?
The market cap of VBIO is approximately $2M, ranking 5,829 within its sector.
What is the 52-week high and low for VBIO?
VBIO has recorded a 52-week high of $78.75 and a low of $2.05.
